Financial Performance - The company's operating revenue for 2021 was ¥320,293,514.52, representing an increase of 18.87% compared to ¥269,441,762.99 in 2020[22] - The net profit attributable to shareholders was a loss of ¥20,325,073.94, an improvement of 61.89% from a loss of ¥53,329,409.90 in the previous year[22] - The net cash flow from operating activities was ¥23,553,573.54, a significant increase of 324.28% compared to -¥10,501,850.45 in 2020[22] - The total assets at the end of 2021 were ¥854,556,164.94, a decrease of 5.85% from ¥907,677,495.31 at the end of 2020[22] - The net assets attributable to shareholders decreased by 2.25% to ¥481,848,410.05 from ¥492,925,341.02 in 2020[22] - The basic earnings per share improved to -¥0.05 from -¥0.13, reflecting a 61.54% increase[22] - The company reported a total of ¥19,058,385.28 in non-recurring gains and losses for 2021, significantly higher than the previous year's amount of ¥4,926,651.22[29] - The company achieved a total revenue of 320,293,514.52 CNY in 2021, representing a year-on-year growth of 18.87%[51] - The net profit attributable to shareholders was -2,032.51 CNY, with a year-on-year increase of 61.89%[51] Revenue Sources - The revenue from product sales, after deducting non-main business income, was ¥303,558,131.42 in 2021, compared to ¥251,479,209.06 in 2020[23] - The company's total revenue for 2021 reached ¥303,558,131.42, representing a year-on-year increase of 20.71%[60] - The company's peptide products generated revenue of 172,370,500.73 CNY, which accounted for 53.81% of total revenue, reflecting a growth of 39.24% year-on-year[57] - The overseas revenue surged by 81.02% to ¥27,913,796.48, driven by increased export activities[60] - The market share of the main product, Thymosin Injection, was approximately 13%, ranking among the top in its category[48] Research and Development - The company invested 3,549.38 CNY in R&D in 2021, accounting for 11.08% of total revenue, although this represented a decrease of 43.07% compared to the previous year[52] - The number of R&D personnel increased by 33.80% to 95 in 2021, representing 22.84% of the total workforce[71] - The company aims to enhance its R&D capabilities and increase investment in R&D, focusing on the development of peptide APIs and formulations[96] - The company has successfully developed multiple peptide drugs and 20 other therapeutic drugs, with its main product, Thymosin Alpha 1 (brand name "Jitai"), approved for use in chronic hepatitis and immune enhancement[43] - The company has advanced laboratory equipment and a strong talent pool for peptide drug research and development, with nearly 10 peptide products in various stages of approval and development[46] Market and Industry Trends - The pharmaceutical industry in China saw a revenue increase of 20.1% year-on-year, reaching ¥2,928.85 billion in 2021, with total profits growing by 77.9%[33] - The domestic peptide drug market is experiencing annual sales growth, with increasing market share for domestic companies due to improved product quality and cost control[93] - The domestic peptide drug market is primarily dominated by foreign brands, indicating significant growth potential for domestic products[94] - The company faces challenges from increased competition in the peptide drug sector, driven by rising investment interest and regulatory changes[94] Governance and Compliance - The company has established a transparent performance evaluation system for its directors and senior management, promoting accountability and clear reward mechanisms[112] - The governance practices of the company align with the regulations set forth by the China Securities Regulatory Commission, ensuring compliance and integrity[113] - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, organization, and finance[115] - The company has established an independent financial accounting system and makes its own financial decisions, with no shared bank accounts with controlling shareholders[116] - The company has implemented an internal audit system with two auditors to oversee financial reporting and internal controls[113] Environmental and Social Responsibility - The company has implemented a comprehensive pollution management system to comply with environmental regulations and reduce risks associated with waste emissions during production[103] - The company has passed environmental impact assessments for multiple projects, including solvent recovery and production expansion projects[169] - There were no administrative penalties imposed on the company due to environmental issues during the reporting period[172] - The company publicly disclosed its pollutant discharge permit execution status and monitoring results on its official website[173] Future Outlook - The company expects to achieve a business revenue of CNY 298.41 million and a total comprehensive income of CNY 8.13 million attributable to shareholders in 2022[97] - The company plans to continue expanding its product pipeline and aims to submit more DMF and ANDA applications in the U.S. and EU markets[49] - The company has provided a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20%[126] - The company plans to enhance market share through marketing strategies and diversify its product line via R&D and acquisitions to mitigate risks associated with product concentration[102] Shareholder Relations - The company has a commitment to prioritize the acquisition of assets or equity from its subsidiaries in case of competitive business operations[180] - The company has established a three-year shareholder return plan for 2021-2023, focusing on cash dividends[182] - The company will conduct annual cash dividends, contingent on positive distributable profits and sufficient cash flow[182] - The company has a structured remuneration decision process based on company performance and individual assessments[131]
双成药业(002693) - 2021 Q4 - 年度财报